Anchorage, AKNCT06764875Now EnrollingIRB Ready

Gastric Cancer Clinical Trial in Anchorage, AK

Access cutting-edge gastric cancer treatment through this phase 3 clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Anchorage location

Preparing your pre-screening questions…

Expert Care in Anchorage

Access gastric cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastric cancer treatment provided free

Apply for This Anchorage Location

Check if you qualify for this gastric cancer clinical trial in Anchorage, AK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Anchorage

    Convenient for AK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Anchorage site if eligible
  4. 4Begin participation

About This Gastric Cancer Study in Anchorage

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

HER2 positive for gastric cancer on a tumor biopsy.
PD-L1 combined positive score (CPS) ≥ 1.
Provision of tumor tissue sample from recent biopsy adequate for HER2 and PD-L1 testing.
Previously untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma.
WHO or Eastern Cooperative Oncology Group performance status of 0 or 1.
Have measurable target disease assessed by the Investigator based on RECIST v1.1.
Have adequate organ and bone marrow function.
LVEF ≥ 50% within 28 days before randomization.
Adequate treatment washout period before randomization.

Exclusion Criteria

Lack of physiological integrity of the upper gastrointestinal tract.
Known dihydropyrimidine dehydrogenase enzyme deficiency.
Contraindication to pembrolizumab or trastuzumab, contraindications to fluoropyrimidine (5-FU and capecitabine) or platinum (cisplatin and oxaliplatin) treatment as per local label.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence.
Persistent toxicities caused by previous anti-cancer therapy.
Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring corticosteroid or anticonvulsant may be included in the study if they have recovered from the acute toxic effect of radiotherapy.
Uncontrolled infection including tuberculosis and active hepatitis A infection.
Uncontrolled infection requiring intravenous (IV) antibiotics, anti-virals, or antifungals.
Recent receipt of live, attenuated vaccine.
Chronic/active HBV or HCV infection unless controlled.
Clinically significant cardiac or psychological conditions.
Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
History of (non-infectious) ILD/pneumonitis, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Lung-specific intercurrent clinically significant illnesses.
Any active non-infectious skin disease requiring systemic treatment.
A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or cell-free and concentrated ascites reinfusion therapy (CART).
History of any of the following: drug-induced severe cutaneous adverse reaction.
Any concurrent antic-ancer treatment with the exception of receptor activator of nuclear factor kappa-B ligand inhibitors.
Have had major surgical procedure recently (excluding placement of vascular access) or recent significant traumatic injury or an anticipated need for major surgery during the study.
Current or prior use of immunosuppressive medication within 14 days before study intervention.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Anchorage?

Yes, this clinical trial (NCT06764875) has an active research site in Anchorage, AK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastric Cancer Treatment Options in Anchorage, AK

If you're searching for gastric cancer treatment options in Anchorage, AK, this clinical trial (NCT06764875) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Anchorage research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced gastric cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastric cancer clinical trials near you to find additional studies recruiting in your area.

More Stomach Cancer Trials in Anchorage, AK

See all stomach cancer clinical trials recruiting in Anchorage — not just this study.

Browse Stomach Cancer Trials in Anchorage →

Browse More Trials by Condition

Stomach Cancer TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Anchorage?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Anchorage, AK